Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

Stopped early · Phase 3

Conditions studied: Alzheimer Disease, Dementia

In brief

This is a multinational, randomized, double blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of 800 mg twice daily MPC-7869 to placebo. Study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.

Key facts

Study ID

NCT00322036

Run by

Myrexis Inc.

People needed

800

Starts

2006-05-01

Expected to finish

2008-12-01

Last updated by the study team

2008-08-05

Who can join

Age: 55 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have had a diagnosis of probable Alzheimer's disease
• Men or women ages greater than or equal to 55 years and living in the community at the time of enrollment (ie, not living in a rest home or nursing care facility).
• Signed the subject Informed Consent Form (ICF) and is willing and able to participate for the duration of the study.
• Ability to read and understand English, Dutch, Danish, Flemish, French, German, Italian, Spanish or Swedish to ensure compliance with cognitive testing and study visit procedures.
• At least 6 years of education, or sufficient work history to exclude mental retardation.
• Female subjects must be surgically sterile or postmenopausal for > 1 year.
• Adequate vision and hearing to participate in study assessments.
• Subjects must have a reliable caregiver who can read, understand and speak same language.

You may not qualify if…

• Current evidence of other causes of dementia.. .
• History of, or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
• Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.
• Major surgery and related complications not resolved within 12 weeks prior to Day 1.
• Previous participation in an MPC-7869 clinical study.

Where it is running

• Study site — Tucson, Arizona, United States
• Study site — Costa Mesa, California, United States
• Study site — San Diego, California, United States
• Study site — New Haven, Connecticut, United States
• Study site — Deerfield Beach, Florida, United States
• Study site — Delray Beach, Florida, United States
• Study site — Gainsville, Florida, United States
• Study site — Hollywood, Florida, United States
• Study site — Miami, Florida, United States
• Study site — Tampa, Florida, United States
• Study site — West Palm Beach, Florida, United States
• Study site — Chicago, Illinois, United States
• Study site — Indianapolis, Indiana, United States
• Study site — Lexington, Kentucky, United States
• Study site — Boston, Massachusetts, United States
• Study site — Farmington Hills, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — Rochester, New York, United States
• Study site — Providence, Rhode Island, United States
• Study site — Charleston, South Carolina, United States
• Study site — Dallas, Texas, United States
• Study site — Salt Lake City, Utah, United States
• Study site — Aalst, Belgium
• Study site — Antwerp, Belgium
• Study site — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.